study for late assessment of the safety and efficacy of biosimilar rituximab

Conditions: Diffuse Large B Cell Lymphoma

Summary: the rtxm83-ac-01-11 study evaluated efficacy and safety outcomes in relation to the use of vivaxxia during 6 treatment cycles (at the investigator's discretion, up to 8 treatment cycles could be administered), followed by 9 months of follow-up. , this follow-up time being sufficient for the analysis of non-inferiority in relation to the reference medicine. however, data on late events of efficacy and safety are of great value to contribute to a robust clinical response and to strengthen confidence in the use of biosimilar medicines. for this reason, libbs farmacêutica proposes this retrospective observational study to collect data on late outcomes of the pivotal study that directed the approval of the biosimilar rituximab (vivaxxia) from the research participants from brazil. the present retrospective observational study lb2002 will sub-analyze selected results of efficacy and safety from study rtxm83-ac-01-11 in participants over 18 years of age randomized in brazil, totaling 28 participants, in addition to evaluating late efficacy and safety outcomes. information on subsequent treatment / protocol should also be collected for participants who have progressive or recurrent disease, instituted by research centers under these conditions. the proposal is to compare descriptively the selected outcomes of efficacy and safety of these participants with the same outcomes selected for the global population in the rtxm83-ac-01-11 study, and also provide late safety and effective data important for anti-neoplastic processes.

evaluate research participants who were refractory to treatment, defined as not having achieved: complete response (cr) or partial response (pr), after 6 treatment cycles in study rtxm83-ac-01-11. evaluate the participants who had a recurrence of the disease, defined as a change from: complete response (cr), after 06 treatment cycles in study rtxm83-ac-01-11, to: progressive disease (pd) until the date of consent (icf) in the lb2002 study. the data of the subsequent treatment / protocol instituted by the research center for progressive or recurrent disease will also be collected. period of analysis of this clinical study * 01-jul-2013 (beginning of the study) to 17-jul-2017 (data in which the last participant of the study rtxm83-ac-01-11 arrived at the last follow-up visit at 9 months after the last dose of treatment): for sub-analysis of efficacy and safety proposed by study rtxm83-ac-01-11: sle, trg and ea, and for exploratory evaluation of refractory disease. * data from randomization in study rtxm83-ac-01-11 to consent data (tcle) in study lb2002: for analysis of slp, sg and for exploratory evaluation of relapse. * date of the final visit of study rtxm83-ac-01-11, considered as fup3, until the date of consent (icf) in study lb2002: for the evaluation of late aes of interest. data collect:for the subanalysis evaluations, the data that have already been collected will be used and are part of the study database rtxm83-ac-01-11. this database will also be considered for exploratory assessment of refractory disease. for late evaluations of safety and efficacy (late adverse events of interest, slp, sg and disease recurrence) and also data on the subsequent treatment / protocol instituted by the research center for progressive disease or disease recurrence, data from medical records available at research centers. finally, all the data necessary to evaluate the objectives established in this study will be imputed in a single electronic case report form (ecrf) developed exclusively for this project.

Eligibility criteria:
inclusion criteria: * free and informed consent to participate in this retrospective, observational study of data collection * research participants from brazil randomized and who received at least one dose of treatment in the rtxm83-ac-01-11 study. exclusion criteria: * not applicable

Keywords: rituximab vivaxxia diffuse large b cell lymphoma biosimilar